Andrew Hirsch, C4 Therapeutics CEO
March 4, 2024 11:30 AM ESTUpdated March 5, 04:29 AM
Deals
R&D

Cor­rect­ed: Mer­ck KGaA bags an­oth­er pro­tein de­grad­er deal for $16M up­front, this time with C4

Ayisha Sharma

News Reporter

In the lat­est de­vel­op­ment in the “high­ly dy­nam­ic” pro­tein de­grad­er space, Mer­ck KGaA has inked a dis­cov­ery agree­ment with C4 Ther­a­peu­tics for two drugs against …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times